Tenax Therapeutics IncNASDAQ:TENX
- LAST PRICE3.4800
- TODAY'S CHANGE (%)-0.1200 (-3.3333%)
- Bid / Lots3.4700/ 2
- Ask / Lots3.5700/ 1
- Open / Previous Close3.5055 / 3.6000
- Day Range
- 52 Week Range
- Volume16,881
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TENX |
|---|---|---|
| 10:10 ET | 400 | 3.5055 |
| 10:33 ET | 1285 | 3.5101 |
| 10:39 ET | 100 | 3.5694 |
| 11:40 ET | 100 | 3.5 |
| 12:16 ET | 1716 | 3.5101 |
| 12:25 ET | 100 | 3.5672 |
| 12:39 ET | 1000 | 3.562 |
| 12:48 ET | 100 | 3.551 |
| 01:14 ET | 100 | 3.51 |
| 01:35 ET | 100 | 3.51 |
| 01:42 ET | 857 | 3.51 |
| 02:22 ET | 703 | 3.5 |
| 02:36 ET | 100 | 3.5 |
| 02:38 ET | 155 | 3.54 |
| 02:40 ET | 6906 | 3.513 |
| 02:54 ET | 100 | 3.5 |
| 03:20 ET | 400 | 3.5418 |
| 03:48 ET | 100 | 3.48 |
| 03:59 ET | 206 | 3.48 |
Apr 9, 2024
Mar 28, 2024
*DJ Tenax Therapeutics 2023 Loss $7.7M >TENX, from 8:39AM ET on Thursday Mar 28, 2024 by Dow Jones
8:39AM ET on Thursday Mar 28, 2024 by Dow JonesTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results, from 8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tenax Therapeutics Inc | 7.0M | -0.1x | --- |
Hepion Pharmaceuticals Inc | 7.1M | -0.1x | --- |
Theriva Biologics Inc | 7.0M | -0.4x | --- |
Adial Pharmaceuticals Inc | 7.0M | -0.3x | --- |
Protagenic Therapeutics Inc | 7.0M | -1.2x | --- |
Lixte Biotechnology Holdings Inc | 7.2M | -1.2x | --- |
Company Information
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Contact Information
- Headquarters
- 101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL, NC, United States 27517
- Phone
- 919-855-2100
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Gerald Proehl
- Chief Executive Officer, Director
- Christopher Giordano
- Interim Chief Financial Officer
- Lawrence Hoffman
- Chief Medical Officer, Director
- Stuart Rich
- Independent Director
- June Almenoff
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.26 |
EPS | $-33.51 |
Book Value | $27.15 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
